ARAF is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ARID1A is altered in 3.45% of rhabdoid tumor patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and rhabdoid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2C status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 is altered in 3.57% of rhabdoid tumor patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is altered in 3.45% of rhabdoid tumor patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF1 is altered in 3.45% of rhabdoid tumor patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SMARCA2 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCA4 is an inclusion eligibility criterion in 3 clinical trials for rhabdoid tumor, of which 2 are open and 1 is closed. Of the trials that contain SMARCA4 status and rhabdoid tumor as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

SMARCB1 is altered in 55.17% of rhabdoid tumor patients [2].

SMARCB1 is an inclusion eligibility criterion in 6 clinical trials for rhabdoid tumor, of which 5 are open and 1 is closed. Of the trials that contain SMARCB1 status and rhabdoid tumor as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (4 open) [3].

SRC is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains SRC status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SS18 is an inclusion eligibility criterion in 2 clinical trials for rhabdoid tumor, of which 1 is open and 1 is closed. Of the trials that contain SS18 status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

SSX1 is an inclusion eligibility criterion in 2 clinical trials for rhabdoid tumor, of which 1 is open and 1 is closed. Of the trials that contain SSX1 status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

SSX2 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains SSX2 status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX2B is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX4 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains SSX4 status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

TET2 is an inclusion eligibility criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].